UnknownPhase 4NCT02681783
PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept
Studying Central serous chorioretinopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sunnybrook Health Sciences Centre
- Principal Investigator
- Radha P. Kohly, MD PhD FRCSCSunnybrook Health Sciences Center
- Intervention
- aflibercept(drug)
- Enrollment
- 90 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2022
Study locations (1)
- Sunnybrook Research Institute, Toronto, Ontario, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02681783 on ClinicalTrials.govOther trials for Central serous chorioretinopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06527326the Study of the Association Between the Gut Microbiota and Central Serous ChorioretinopathySecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGNCT06346405Central Serous Chorioretinopathy and Micropulse Laser TreatmentFondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGNANCT05570591Subthreshold Nanosecond Laser for Non-resolving Central Serous ChorioretinopathyNova Eye Medical Pty Ltd.
- RECRUITINGNCT05589974Choroidal Blood Flow in Acute and Chronic Central Serous ChorioretinopathyHelse Stavanger HF